Chuck Simonton on Leadership, Innovations and Industry
33: Chuck Simonton on Leadership, Innovations and Industry

Average (ratings)
No ratings
 
  Your rating

In this week’s Parallax, host Ankur Kalra is joined by Charles (Chuck) Simonton, Vice President and Chief Medical Officer of Abiomed. Chuck talks about how his father’s leadership and service as a Methodist minister inspired him to become a doctor. He recalls the dawn of interventional cardiology: the birth of angioplasty and stenting. Drawing from his experiences as a trialist who worked with some of the most influential minds, he offers practical tips to young doctors. Finally, Ankur asks Chuck about the Impella device controversy and the recent decision of Abiomed to accelerate their clinical research.

 

How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?

 

Tune in to listen to this week’s episode of Parallax.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Submit your questions to Ankur via: podcast@radcliffe-group.com.


Read MoreRead Less
Share
Up Next
EP34 • Apr 23, 2020
In this week’s episode Ankur Kalra asks Dr Suzanne J Baron, Director of Interventional Cardiovascular Research at Lahey Hospital & Medical Center: How do we measure the value of a novel technology?

During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.

In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
Read More
All Episodes
EP42 • Feb 09, 2021 • 1m 1s
Mallory was not prepared when she underwent her first heart surgery in seventh grade: She was hoping to regain her stamina, instead she experienced what she describes as a loss of self. Mallory was born with a rare heart disease called a Ebstein’s anomaly.
Read More
EP41 • Jan 25, 2021 • 1m
How does Dr Mehra think about building opportunities? What were his formative experiences? How does he think about the role of mentorship in medicine? What is Dr Mehra’s message to our listeners?Dr Mehra does not frame his experiences as failures or successes; he looks at all events with one question in mind: What can I learn from this?

In this week’s episode Ankur’s guest is Dr Mandeep R Mehra, Medical Director of Brigham Heart and Vascular Center and Professor of Medicine at Harvard Medical School.
Read More
EP40 • Jan 11, 2024
Podcast test for recombee
Read More
EP39 • Jan 21, 2021 • 50
In the first Parallax episode of 2021, Ankur welcomed back Sukh Nijjer from Imperial College London to review the most impactful events and advances in cardiology from 2020.

Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
Read More
EP38 • Dec 17, 2020
In the Season 2 finale, Ankur Kalra is joined by the legendary Martin B Leon, Professor at Columbia University, director of the TCT and chairman emeritus of the CRF.

What makes Dr Martin B Leon tick? What is his message to cardiologists and/or researchers at the beginning of their careers? How did the pandemic and his work as a clinician in New York change his perspective?
Read More
EP37 • Dec 30, 2020
This week Parallax welcomed its first non-physician/researcher guest: health advocate Lindsay Davis. Lindsay, ballerina with ambitions to study at Julliard, was experiencing the symptoms of hypertrophic cardiomyopathy (HCM) from her early teens, but she had not been diagnosed until she was 17.

In this episode Ankur asks Lindsay about her treatment path. Lindsay recalls her own journey to taking control of her condition and the important role of information in patient adherence. Lindsay, former Miss Ohio, talks how she used the pageant to create awareness. Lindsay talks about work in state legislation and her plans for 2021.
Read More
EP36 • Apr 23, 2020
In 2020, women still only represent 16% of editorial boards.

US Cardiology Review journal, has recently seen a 7-fold increase in female editorial board members in response to journal-based strategic initiatives and the stellar work of USC editorial board leadership, Ankur Kalra (Editor in Chief) and Bill Gogas (Deputy Editor in Chief), who were keen to drive this change. With thanks to Dr Anastasia Mihailidou’s tenure as a new board member and her suggested nominees, ten new female board members have recently joined US Cardiology Review’s editorial board.
Read More
EP35 • Apr 23, 2020
One of the first things painted by the young Mike Gibson, today Professor of Medicine at Harvard, researcher and interventional cardiologist, was a cloud. Years later while painting angiograms Dr Gibson came up with the idea of myocardial blush: The blush was that cloud of dye in the heart muscle.

In this episode, Mike opens up about his childhood in Stilwell, Oklahoma. Ankur and Mike discuss how the inductive quality of art can complement the deductive principles of science. Mike recalls earlier stages of his career and warns about the blinding effect of the ego-driven, competitive culture of cardiology. Ankur asks Mike about fatherhood and about his role as an educator. 

What does it mean to be fearless as a medical professional? How can you protect yourself from the emotional toll of the profession? What is Mike’s advice to early career cardiologists?

Sponsored by Edwards.
Read More
EP34 • Apr 23, 2020
In this week’s episode Ankur Kalra asks Dr Suzanne J Baron, Director of Interventional Cardiovascular Research at Lahey Hospital & Medical Center: How do we measure the value of a novel technology?

During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.

In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
Read More
EP33 • Apr 23, 2020
In this week’s Parallax, host Ankur Kalra is joined by Charles (Chuck) Simonton, Vice President and Chief Medical Officer of Abiomed. Chuck talks about how his father’s leadership and service as a Methodist minister inspired him to become a doctor. He recalls the dawn of interventional cardiology: the birth of angioplasty and stenting. Drawing from his experiences as a trialist who worked with some of the most influential minds, he offers practical tips to young doctors. Finally, Ankur asks Chuck about the Impella device controversy and the recent decision of Abiomed to accelerate their clinical research.

How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?
Read More
EP02 • Apr 23, 2020

Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.



Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.



Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
EP01 • Apr 23, 2020
In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More